Pharmaceuticals, Biotechnology and Life Sciences
BERKELEY, Calif.–(BUSINESS WIRE)–Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today the successful completion of an oversubscribed $115 million Series C financing. Proceeds from the financ…
Important Regulatory Milestone Provides Runway to Move XTMAB-16 into the Clinical Phase
CHICAGO–(BUSINESS WIRE)–Xentria Inc., a biopharmaceutical company focused on developing novel biologics and biosimilars to address unmet clinical needs, today an…
The clinical solution provider extends its geographical coverage to Oceania
BOSTON, Mass.–(BUSINESS WIRE)–KCR, the international clinical development solutions provider, today announced the establishment of a new branch in Sydney, Australia. The new…
CARDIFF, Wales–(BUSINESS WIRE)–TrakCel, a leading supplier of cellular orchestration solutions supporting the cell and gene therapy industry, today announces that it has closed its latest funding round led by AmerisourceBergen and Labcorp (NYSE: LH)….
DUBLIN–(BUSINESS WIRE)–The “Healthcare Logistics Market in Canada 2020-2024” report has been added to ResearchAndMarkets.com’s offering.
Global Healthcare Logistics Market in Canada 2020-2024
The healthcare logistics market in Canada is poised to …
CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that the U.S. Food and Drug Administration (FDA) has…
AZR-MD-001 meets primary endpoints of significant improvement in signs and symptoms of MGD and restoration of gland function
TEL AVIV, Israel & MELBOURNE, Australia–(BUSINESS WIRE)–Azura Ophthalmics Ltd., a clinical-stage company developing innovati…
− Ovid eligible to receive up to $856M in payments, including a $196M upfront payment, regulatory and commercial milestone payments and tiered double-digit royalties on product sales
− Potential first-in-class therapy reduced seizure frequency in chi…
Expects preliminary Phase 1/2 safety and biomarker and preliminary clinical data for TSHA-101 in GM2 gangliosidosis from the Queen’s University study in second half of 2021 and by year-end 2021, respectively
Plans to initiate Phase 1/2 clinical trial…
LEEDS, England–(BUSINESS WIRE)–4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) – a novel class of drug derived from the microbiome, today announced that 4D management will present at …